Last reviewed · How we verify

Atimos® — Competitive Intelligence Brief

Atimos® (Atimos®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting muscarinic antagonist (LAMA). Area: Respiratory / Pulmonology.

marketed Long-acting muscarinic antagonist (LAMA) M3 muscarinic receptor Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Atimos® (Atimos®) — Chiesi Farmaceutici S.p.A.. Atimos is a tiotropium bromide inhalation powder that acts as a long-acting anticholinergic (muscarinic antagonist) to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Atimos® TARGET Atimos® Chiesi Farmaceutici S.p.A. marketed Long-acting muscarinic antagonist (LAMA) M3 muscarinic receptor
Solifenacin + Mirabegron Solifenacin + Mirabegron University of Aarhus marketed Antimuscarinic + Beta-3 adrenergic agonist combination M3 muscarinic receptor (solifenacin) and beta-3 adrenergic receptor (mirabegron)
Tolterodine 6 Tolterodine 6 KYU-SUNG LEE marketed Muscarinic receptor antagonist M2 and M3 muscarinic receptors
albuterol plus tiotropium albuterol plus tiotropium IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy marketed Combination bronchodilator (SABA + LAMA) Beta-2 adrenergic receptor (albuterol); M3 muscarinic receptor (tiotropium)
Umeclidinium/Vilanterol 62.5/25 mcgs Umeclidinium/Vilanterol 62.5/25 mcgs National Institute of Respiratory Diseases, Mexico marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) M3 muscarinic receptor; beta-2 adrenergic receptor
Olodaterol-Tiotropium Olodaterol-Tiotropium Fraunhofer-Institute of Toxicology and Experimental Medicine marketed Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination) Beta-2 adrenergic receptor; M3 muscarinic receptor
Vilanterol and Umeclidinium Bromide Vilanterol and Umeclidinium Bromide Samsung Medical Center marketed Long-acting beta-2 agonist / Long-acting muscarinic antagonist combination (LABA/LAMA) Beta-2 adrenergic receptor; M3 muscarinic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting muscarinic antagonist (LAMA) class)

  1. GlaxoSmithKline · 9 drugs in this class
  2. AstraZeneca · 3 drugs in this class
  3. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
  4. Chiesi Farmaceutici S.p.A. · 1 drug in this class
  5. IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 drug in this class
  6. Lupin, Inc. · 1 drug in this class
  7. Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Atimos® — Competitive Intelligence Brief. https://druglandscape.com/ci/atimos. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: